TrialBMJ open2014

Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial.

Frank Waldron-Lynch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.